Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174177 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173095 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173886 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173917 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2176592 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173350 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2175508 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL423932 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173923 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL1824570 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | OSAKA UNIVERSITY (JP) | 2024-05-09 | — | — | US | disclosed |
| US-11939421-B2 | Or relating to curing agents | HEXCEL COMPOSITES LIMITED (GB) | 2024-03-26 | — | — | US | disclosed |
| US-11879052-B2 | Curatives | HEXCEL COMPOSITES LIMITED (GB) | 2024-01-23 | — | — | US | disclosed |
| US-11866705-B2 | Small cell lung cancer therapeutic agent containing oligonucleotide | Osaka Univerity (JP) | 2024-01-09 | — | — | US | disclosed |
| EP-4299744-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | OSAKA UNIVERSITY (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2023-12-12 | — | — | US | disclosed |
| WO-2023224108-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | 株式会社GF・Mille | 2023-11-23 | — | — | WO | disclosed |
| US-6093722-A | ADMINISTERING AN ANTICANCER DRUG N-3-OXO-4-AZA-5 ALPHA-ANDROST-1-ENE-17 BETA-CARBOXAMIDE, A TESTOSTERONE 5-ALPHA REDUCTASE ENZYME INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 2000-07-25 | — | — | US | disclosed |
| US-5925664-A | VISION DEFECTS | SANKYO COMPANY, LIMITED (JP) | 1999-07-20 | — | — | US | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0795326-A1 | OCULAR TENSION DEPRESSANT | SANKYO COMPANY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
| CN-1157286-A | N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
| CN-1148809-A | intraocular pressure lowering agent | SANKYO CO (JP) | 1997-04-30 | — | — | CN | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| CN-1102640-A | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory and psychiatric disorders | SANKYO CO (JP) | 1995-05-17 | — | — | CN | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840530-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | FFAR1 213/4885CPT2 3742/4885TDP1 4846/4885 |
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | UPF1, RBM17, NSUN2 | FFAR1 2468/4885CPT2 4741/4885TDP1 328/4885 |
| US-11939421-B2 | Or relating to curing agents | FABP4, RARA, ADIPOR1 | FFAR1 327/4885CPT2 227/4885TDP1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.